Barbui Corrado, Bertolini Federico, Bartoli Francesco, Calandra Carmela, Callegari Camilla, Carrà Giuseppe, D'Agostino Armando, Lucii Claudio, Martinotti Giovanni, Mastromo Daniele, Moretti Daniele, Monzani Emiliano, Porcellana Matteo, Prestia Davide, Ostuzzi Giovanni
WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation; Department of Neuroscience, Biomedicine and Movement Sciences; Section of Psychiatry, University of Verona, Verona, Italy.
Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy.
Ther Adv Psychopharmacol. 2020 Dec 22;10:2045125320978102. doi: 10.1177/2045125320978102. eCollection 2020.
Long acting injectable (LAI) antipsychotics have been claimed to ensure treatment adherence and possibly reduce the daily burden of oral formulations. So far, only surveys investigating the theoretical prescribing attitudes of clinicians have been employed. On this basis, we aimed to investigate reasons for prescribing LAIs in a real-world, unselected sample of patients.
The STAR Network Depot Study is an observational, multicentre study consecutively enrolling adults initiating a LAI over a 12-months period. Clinical severity was assessed with the Brief Psychiatric Rating Scale, and patient's attitude toward medications with the Drug Attitude Inventory 10 items. Psychiatrists recorded reasons for LAI prescribing for each study participant. Responses were grouped into six non-mutually exclusive categories: aggressiveness, patient engagement, ease of drug taking, side-effects, stigma, adherence.
Of the 451 patients included, two-thirds suffered from chronic psychoses. Improving patient engagement with the outpatient psychiatric service was the most common reason for prescribing LAIs (almost 80% of participants), followed by increasing treatment adherence (57%), decreasing aggressiveness (54%), and improving ease of drug taking (52%). After adjusting for confounders, logistic regression analyses showed that reasons for LAI use were associated with LAI choice (e.g. first-generation LAIs for reducing aggressiveness).
Despite the wide availability of novel LAI formulation and the emphasis on their wider use, our data suggest that the main reasons for LAI use have remained substantially unchanged over the years, focusing mostly on improving patient's engagement. Further, clinicians follow implicit prescribing patterns when choosing LAIs, and this may generate hypotheses for future experimental studies.
长效注射用(LAI)抗精神病药物据称可确保治疗依从性,并可能减轻口服制剂的日常负担。到目前为止,仅采用了调查临床医生理论处方态度的研究。在此基础上,我们旨在调查在真实世界中未经过筛选的患者样本中使用长效注射用抗精神病药物的原因。
STAR网络长效注射剂研究是一项观察性多中心研究,连续纳入在12个月期间开始使用长效注射用抗精神病药物的成年人。使用简明精神病评定量表评估临床严重程度,使用10项药物态度量表评估患者对药物的态度。精神科医生记录每位研究参与者使用长效注射用抗精神病药物的原因。回答被分为六个非相互排斥的类别:攻击性、患者参与度、服药便利性、副作用、耻辱感、依从性。
在纳入的451名患者中,三分之二患有慢性精神病。改善患者对门诊精神科服务的参与度是使用长效注射用抗精神病药物最常见的原因(近80%的参与者),其次是提高治疗依从性(57%)、降低攻击性(54%)和提高服药便利性(52%)。在对混杂因素进行调整后,逻辑回归分析表明,使用长效注射用抗精神病药物的原因与长效注射用抗精神病药物的选择有关(例如,第一代长效注射用抗精神病药物用于降低攻击性)。
尽管新型长效注射用制剂广泛可得且强调其更广泛的使用,但我们的数据表明,多年来使用长效注射用抗精神病药物的主要原因基本未变,主要集中在提高患者的参与度上。此外,临床医生在选择长效注射用抗精神病药物时遵循隐性处方模式,这可能为未来的实验研究提出假设。